ADXS Advaxis, Inc.

8.51
+0  (0%)
Previous Close 8.50
Open 8.49
Price To book 3.18
Market Cap 342.91M
Shares 40,295,000
Volume 699,760
Short Ratio 14.87
Av. Daily Volume 709,743

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated 2H 2017.
Axalimogene filolisbac
Cervical cancer
Phase 1/2 updated data due 2H 2017.
Axalimogene filolisbac + durvalumab
Recurrent or refractory HPV-associated cervical cancer and head & neck cancer
Completed the first two dose-escalation cohorts and launched the third dose-escalation cohort in April 2016. Part B combination portion of trial commenced October 2016. Enrollment to be completed by end of 2017.
ADXS-PSA and Keytruda
Castrate-resistant prostate cancer
Announced Phase 3 first patient dosed - February 6, 2017.
Axalimogene filolisbac - AIM2CERV Trial
High-risk, locally advanced cervical cancer
Phase 2 top-line data released October 24, 2016. Second stage was not completed due to the clinical hold in 2015.
Axalimogene filolisbac - GOG 0265 study
Cervical cancer
Phase 1b ongoing.
ADXS-HER2
HER2-driven malignancies - cancer
Phase 2 initiated June 2016. Preliminary update due 2H 2017.
Axalimogene filolisbac
Anal cancer (FAWCETT)

Latest News

  1. Advaxis, Inc. :ADXS-US: Earnings Analysis: Q1, 2017 By the Numbers : March 22, 2017
  2. ADVAXIS, INC. Financials
  3. Advaxis Presents Oral Late-breaking Data on Phase 2 GOG-0265 Study of Axalimogene Filolisbac at SGO’s Annual Meeting on Women’s Cancer
  4. Advaxis to Present at the 2017 Barclays Global Healthcare Conference
  5. Advaxis, Inc. breached its 50 day moving average in a Bullish Manner : ADXS-US : March 10, 2017
  6. Advaxis Appoints Al Blunt, M.D., as its Vice President of Medical
  7. Advaxis stock jumps 10% after FDA okays clinical trials for Amgen-partnered cancer drug
  8. Advaxis Announces FDA Acceptance of IND for Groundbreaking Personalized Neoepitope Immunotherapy, ADXS-NEO
  9. These 5 Stocks Under $10 Could Explode Up Soon
  10. Advaxis to Host Research Reception at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer
  11. Advaxis Inks Cancer Drug Deal with Sellas
  12. Advaxis and SELLAS Announce Licensing Agreement for Development of WT1 Antigen-Targeting Immunotherapy
  13. Advaxis and SELLAS Announce Licensing Agreement for Development of WT1 Antigen-Targeting Immunotherapy
  14. Advaxis Announces First Patient Dosed in Global Phase 3 AIM2CERV Trial for High-risk, Locally Advanced Cervical Cancer
  15. GOG-0265 Study in Metastatic Cervical Cancer Selected for Late-Breaking Data Presentation at the Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer
  16. Advaxis, Inc. breached its 50 day moving average in a Bullish Manner : ADXS-US : January 26, 2017
  17. New Published Research Reveals that Cervical Cancer Mortality Rates May Be Significantly Higher in the United States than Previously Reported
  18. Advaxis, Inc. – Value Analysis (NASDAQ:ADXS) : January 13, 2017
  19. Advaxis, Inc. breached its 50 day moving average in a Bullish Manner : ADXS-US : January 12, 2017
  20. ADVAXIS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits